TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,499,412 | +238.8% | 3,635,281 | +482.0% | 0.02% | +220.0% |
| Q2 2023 | $9,593,902 | +37841.6% | 624,603 | -44.4% | 0.01% | -64.3% |
| Q1 2023 | $25,286 | +39.6% | 1,124,338 | +30.6% | 0.01% | +40.0% |
| Q4 2022 | $18,108 | -99.9% | 861,045 | +23.2% | 0.01% | 0.0% |
| Q3 2022 | $17,223,000 | +268.6% | 698,999 | +262.5% | 0.01% | +233.3% |
| Q2 2022 | $4,672,000 | -78.5% | 192,816 | -77.1% | 0.00% | -75.0% |
| Q1 2022 | $21,740,000 | +141.3% | 843,629 | +190.6% | 0.01% | +140.0% |
| Q4 2021 | $9,011,000 | +126.6% | 290,303 | +77.1% | 0.01% | +150.0% |
| Q3 2021 | $3,976,000 | +932.7% | 163,948 | +521.7% | 0.00% | – |
| Q2 2021 | $385,000 | -96.5% | 26,371 | -93.9% | 0.00% | -100.0% |
| Q1 2021 | $10,879,000 | -45.1% | 435,682 | -40.1% | 0.01% | -42.9% |
| Q4 2020 | $19,819,000 | – | 727,176 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |